Subclinical TB With Innovative Modified Short-course Regimens
Status:
Active, not recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This study is a randomized controlled trial among subclinical tuberculosis patients aiming to
assess whether the standard treatment duration can be shortened to 17 weeks or even 8 weeks
without changing the current anti-tuberculosis drugs or dosages.